Inhibitory effect of probiotic Escherichia coli strain Nissle 1917 on adhesion to and invasion of intestinal epithelial cells by adherent-invasive E. coli strains isolated from patients with Crohn's disease

Alimentary Pharmacology and Therapeutics

Volumn 18, Issue 1, 2003, Pages 45-56

  Boudeau, J ^a   Glasser, A L ^a   Julien, S ^a   Colombel, J F ^b   Darfeuille Michaud, A ^a,c  

^a UNIVERSITÉ CLERMONT AUVERGNE   (France)

^b INSERM   (France)

^c Faculté de Pharmacie   (France)

Author keywords

[No Author keywords available]

Indexed keywords

PROBIOTIC AGENT;

ARTICLE; BACTERIAL STRAIN; BACTERIUM ADHERENCE; BACTERIUM ISOLATE; BACTERIUM ISOLATION; CELL CULTURE; COLONY FORMING UNIT; CROHN DISEASE; ESCHERICHIA COLI; ESCHERICHIA COLI NISSLE 1917; HUMAN; HUMAN CELL; INTESTINE EPITHELIUM CELL; NONHUMAN; PRIORITY JOURNAL;

BACTERIAL ADHESION; CELLS, CULTURED; CROHN DISEASE; EPITHELIAL CELLS; ESCHERICHIA COLI; HUMANS; PROBIOTICS;

EID: 0042344991     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2036.2003.01638.x     Document Type: Article

References (56)

1. Podolsky DK. Inflammatory bowel disease. N Engl J Med 2002; 347(6): 417-29.
2. Zumla A, James DG. Granulomatous infections: etiology and classification. Clin Infect Dis 1996; 23(1): 146-58.
3. Hugot JP, Chamaillard M, Zouali H, et al. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature 2001; 411(6837): 599-603.
4. Ogura Y, Bonen DK, Inohara N, et al. A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature 2001; 411(6837): 603-6.
5. Girardin SE, Boneca IG, Viala J, et al. Nod2 is a general sensor of peptidoglycan through muramyl dipeptide (MDP) detection. J Biol Chem 2003; 13: 13.
6. Inohara N, Ogura Y, Fontalba A, et al. Host recognition of bacterial muramyl dipeptide mediated through NOD2: implications for Crohn's disease. J Biol Chem 2003; 4: 4.
7. Tieng V, Le Bouguenec C, du Merle L, et al. Binding of Escherichia coli adhesin AfaE to CD55 triggers cell-surface expression of the MHC class I-related molecule MICA. Proc Natl Acad Sci USA 2002; 99(5): 2977-82.
8. Boudeau J, Glasser AL, Neut C, et al. Invasive ability of Escherichia coli strains isolated from ileal mucosa in Crohn's disease. Gastroenterology 2000; 118(S2): A1847(Abstract).
9. Darfeuille-Michaud A, Neut C, Barnich N, et al. Presence of adherent Escherichia coli strains in ileal mucosa of patients with Crohn's disease. Gastroenterology 1998; 115(6): 1405-13.
10. Lederman E, Neut C, Desreumaux P, et al. Bacterial overgrowth in the neoterminal ileum after ileocolonic resection for Crohn's disease. Gastroenterology 1997; 112: A1023 (Abstract).
11. Boudeau J, Glasser AL, Masseret E, Joly B, Darfeuille-Michaud A. Invasive ability of an Escherichia coli strain isolated from the ileal mucosa of a patient with Crohn's disease. Infect Immun 1999; 67(9): 4499-509.
12. Boudeau J, Barnich N, Darfeuille-Michaud A. Type 1 pili-mediated adherence of Escherichia coli strain LF82 isolated from Crohn's disease is involved in bacterial invasion of intestinal epithelial cells. Mol Microbiol 2001; 39(5): 1272-84.
13. Glasser AL, Boudeau J, Barnich N, Perruchot MH, Colombel JF, Darfeuille-Michaud A. Adherent invasive Escherichia coli strains from patients with Crohn's disease survive and replicate within macrophages without inducing host cell death. Infect Immun 2001; 69(9): 5529-37.
14. Darfeuille-Michaud A. Adherent-invasive Escherichia coli: a putative new E. coli pathotype associated with Crohn's disease. Int J Med Microbiol 2002; 292(3-4): 185-93.
15. Colombel JF, Lemann M, Cassagnou M, et al. A controlled trial comparing ciprofloxacin with mesalazine for the treatment of active Crohn's disease. Groupe d'Etudes Therapeutiques des Affections Inflammatoires Digestives (GETAID). Am J Gastroenterol 1999; 94(3): 674-8.
16. Rutgeerts P, Hiele M, Geboes K, et al. Controlled trial of metronidazole treatment for prevention of Crohn's recurrence after ileal resection. Gastroenterology 1995; 108(6): 1617-21.
17. Sutherland L, Singleton J, Sessions J, et al. Double blind, placebo controlled trial of metronidazole in Crohn's disease. Gut 1991; 32(9): 1071-5.
18. Turunen UM, Farkkila MA, Hakala K, et al. Long-term treatment of ulcerative colitis with ciprofloxacin: a prospective. double-blind, placebo-controlled study. Gastroenterology 1998; 115(5): 1072-8.
19. Prantera C, Zannoni F, Scribano ML, et al. An antibiotic regimen for the treatment of active Crohn's disease: a randomized, controlled clinical trial of metronidazole plus ciprofloxacin. Am J Gastroenterol 1996; 91(2): 328-32.
20. Greenbloom SL, Steinhart AH, Greenberg GR. Combination ciprofloxacin and metronidazole for active Crohn's disease. Can J Gastroenterol 1998; 12(1): 53-6.
21. Saarela M, Mogensen G, Fonden R, Matto J, Mattila-Sandholm T. Probiotic bacteria: safety, functional and technological properties. J Biotechnol 2000; 84(3): 197-215.
22. Shanahan F. Inflammatory bowel disease: immunodiagnostics, immunotherapeutics, and ecotherapeutics. Gastroenterology 2001; 120(3): 622-35.
23. Madsen KL. The use of probiotics in gastrointestinal disease. Can J Gastroenterol 2001; 15(12): 817-22.
24. Isolauri E, Kirjavainen PV, Salminen S. Probiotics: a role in the treatment of intestinal infection and inflammation? Gut 2002; 50(Suppl. 3): III54-9.
25. Fooks LJ, Gibson GR. Probiotics as modulators of the gut flora. Br J Nutr 2002; 88(Suppl. 1): S39-49.
26. Arvola T, Laiho K, Torkkeli S, et al. Prophylactic Lactobacillus GG reduces antibiotic-associated diarrhea in children with respiratory infections: a randomized study. Pediatrics 1999; 104(5): e64.
27. Coconnier MH, Lievin V, Hemery E, Servin AL. Antagonistic activity against Helicobacter infection in vitro and in vivo by the human Lactobacillus acidophilus strain LB. Appl Environ Microbiol 1998; 64(11): 4573-80.
28. Koga T, Mizobe T, Takumi K. Antibacterial activity of Lactobacillus species against Vibrio species. Microbiol Res 1998; 153(3): 271-5.
29. Velraeds MM, van der Mei HC, Reid G, Busscher HJ. Inhibition of initial adhesion of uropathogenic Enterococcus faecalis by biosurfactants from Lactobacillus isolates. Appl Environ Microbiol 1996; 62(6): 1958-63.
30. Vignolo GM, Suriani F, Pesce de Ruiz Holgado A, Oliver G. Antibacterial activity of Lactobacillus strains isolated from dry fermented sausages. J Appl Bacteriol 1993; 75(4): 344-9.
31. Coconnier MH, Lievin V, Lorrot M, Servin AL. Antagonistic activity of Lactobacillus acidophilus LB against intracellular Salmonella enterica serovar Typhimurium infecting human enterocyte-like Caco-2/TC-7 cells. Appl Environ Microbiol 2000; 66(3): 1152-7.
32. Hudault S, Lievin V, Bernet-Camard MF, Servin AL. Antagonistic activity exerted in vitro and in vivo by Lactobacillus casei (strain GG) against Salmonella typhimurium C5 infection. Appl Environ Microbiol 1997; 63(2): 513-8.
33. Gionchetti P, Rizzello F, Venturi A, et al. Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial. Gastroenterology 2000; 119(2): 305-9.
34. Prantera C, Scribano ML, Falasco G, Andreoli A, Luzi C. Ineffectiveness of probiotics in preventing recurrence after curative resection for Crohn's disease: a randomised controlled trial with Lactobacillus GG. Gut 2002; 51(3): 405-9.
35. Guslandi M, Mezzi G, Sorghi M, Testoni PA. Saccharomyces boulardii in maintenance treatment of Crohn's disease. Dig Dis Sci 2000; 45(7): 1462-4.
36. Venturi A, Gionchetti P, Rizzello F, et al. Impact on the composition of the faecal flora by a new probiotic preparation: preliminary data on maintenance treatment of patients with ulcerative colitis. Aliment Pharmacol Ther 1999; 13(8): 1103-8.
37. Gupta P, Andrew H, Kirschner BS, Guandalini S. Is Lactobacillus GG helpful in children with Crohn's disease? Results of a preliminary, open-label study. J Pediatr Gastroenterol Nutr 2000; 31(4): 453-7.
38. Malchow HA. Crohn's disease and Escherichia coli. A new approach in therapy to maintain remission of colonic Crohn's disease? J Clin Gastroenterol 1997; 25(4): 653-8.
39. Rembacken BJ, Snelling AM, Hawkey PM, Chalmers DM, Axon AT. Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trial. Lancet 1999; 354(9179): 635-9.
40. Kruis W, Schutz E, Fric P, Fixa B, Judmaier G, Stolte M. Double-blind comparison of an oral Escherichia coli preparation and mesalazine in maintaining remission of ulcerative colitis. Aliment Pharmacol Ther 1997; 11(5): 853-8.
41. Lodinova-Zadnikova R, Sonnenborn U. Effect of preventive administration of a nonpathogenic Escherichia coli strain on the colonization of the intestine with microbial pathogens in newborn infants. Biol Neonate 1997; 71(4): 224-32.
42. Madsen K, Cornish A, Soper P, et al. Probiotic bacteria enhance murine and human intestinal epithelial barrier function. Gastroenterology 2001; 121(3): 580-91.
43. Borruel N, Carol M, Casellas F, et al. Increased mucosal tumour necrosis factor alpha production in Crohn's disease can be downregulated ex vivo by probiotic bacteria. Gut 2002; 51(5): 659-64.
44. Dunne C, Murphy L, Flynn S, et al. Probiotics; from myth to reality. Demonstration of functionality in animal models of disease and in human clinical trials. Antonie Van Leeuwenhoek 1999; 76(1-4): 279-92.
45. Neeser JR, Granato D, Rouvet M, Servin A, Teneberg S, Karlsson KA. Lactobacillus johnsonii La1 shares carbohydrate-binding specificities with several enteropathogenic bacteria. Glycobiology 2000; 10(11): 1193-9.
46. Bernet MF, Brassart D, Neeser JR, Servin AL. Adhesion of human bifidobacterial strains to cultured human intestinal epithelial cells and inhibition of enteropathogen-cell interactions. Appl Environ Microbiol 1993; 59(12): 4121-8.
47. Bernet MF, Brassart D, Neeser JR, Servin AL. Lactobacillus acidophilus LA 1 binds to cultured human intestinal cell lines and inhibits cell attachment and cell invasion by enterovirulent bacteria. Gut 1994; 35(4): 483-9.
48. Coconnier MH, Klaenhammer TR, Kerneis S, Bernet MF, Servin AL. Protein-mediated adhesion of Lactobacillus acidophilus BG2FO4 on human enterocyte and mucus-secreting cell lines in culture. Appl Environ Microbiol 1992; 58(6): 2034-9.
49. Chauviere G, Coconnier MH, Kerneis S, Darfeuille-Michaud A, Joly B, Servin AL. Competitive exclusion of diarrheagenic Escherichia coli (ETEC) from human enterocyte-like Caco-2 cells by heat-killed Lactobacillus. FEMS Microbiol Lett 1992; 70(3): 213-7.
50. Coconnier MH, Lievin V, Bernet-Camard MF, Hudault S, Servin AL. Antibacterial effect of the adhering human Lactobacillus acidophilus strain LB. Antimicrob Agents Chemother 1997; 41(5): 1046-52.
51. Bernet-Camard MF, Lievin V, Brassart D, Neeser JR, Servin AL, Hudault S. The human Lactobacillus acidophilus strain LA1 secretes a nonbacteriocin antibacterial substance(s) active in vitro and in vivo. Appl Environ Microbiol 1997; 63(7): 2747-53.
52. Hudault S, Guignot J, Servin AL. Escherichia coli strains colonising the gastrointestinal tract protect germfree mice against Salmonella typhimurium infection. Gut 2001; 49(1): 47-55.
53. Blum G, Marre R, Hacker J. Properties of Escherichia coli strains of serotype O6. Infection 1995; 23(4): 234-6.
54. Stentebjerg-Olesen B, Chakraborty T, Klemm P. Type 1 fimbriation and phase switching in a natural Escherichia coli fimB null strain. Nissle 1917. J Bacteriol 1999; 181(24): 7470-8.
55. Sokurenko EV, Courtney HS, Maslow J, Siitonen A, Hasty DL. Quantitative differences in adhesiveness of type 1 fimbriated Escherichia coli due to structural differences in fimH genes. J Bacteriol 1995; 177(13): 3680-6.
56. Sokurenko EV, Chesnokova V, Dykhuizen DE, et al. Pathogenic adaptation of Escherichia coli by natural variation of the FimH adhesin. Proc Natl Acad Sci USA 1998; 95(15): 8922-6.